GeoVax Reveals Promising Gedeptin® Clinical Data for Advanced Head and Neck Cancer Treatment
TL;DR
Gedeptin presents promising data for solid tumors, offering potential competitive advantage in cancer treatment.
Gedeptin uses viral-vectored gene therapy with intratumoral and intravenous administration, targeting quiescent tumor cells for selective cytotoxicity.
Gedeptin's clinical results show efficacy in advanced cancers, paving the way for novel tumor-targeted therapies to improve patient outcomes.
GeoVax's Gedeptin therapy at AACR unveils innovative gene-directed prodrug approach, revolutionizing cancer treatment strategies.
Found this article helpful?
Share it with your network and spread the knowledge!
Researchers from GeoVax Labs have presented promising clinical data for Gedeptin®, a novel gene-directed enzyme prodrug therapy targeting advanced head and neck cancers, at the American Association for Cancer Research Annual Meeting.
The Phase 1/2 clinical trial evaluated Gedeptin's safety and efficacy in eight heavily pretreated patients with advanced head and neck cancers. Patients received up to five treatment cycles involving intratumoral Gedeptin injection followed by intravenous fludarabine administration.
Key findings revealed median progression-free and overall survival of 7.0 months, with several patients achieving stable disease despite extensive prior therapies. Critically, the treatment demonstrated minimal side effects, with injection site pain being the most common adverse event.
The study's success has prompted GeoVax to advance preparations for a Phase 2 clinical trial. The upcoming study will evaluate Gedeptin in combination with pembrolizumab (Keytruda®) as a neoadjuvant therapy for relapsed squamous cell head and neck cancer.
Gedeptin's unique mechanism involves using a non-replicating adenoviral vector to selectively target and kill cancer cells by enzymatically converting a prodrug into a cytotoxic compound. This approach potentially offers a novel treatment strategy for challenging solid tumors.
The research represents a significant step in developing targeted cancer therapies that minimize systemic toxicity while potentially improving patient outcomes. By focusing on selectively destroying cancer cells within the tumor microenvironment, Gedeptin demonstrates promise for treating advanced, treatment-resistant cancers.
Curated from NewMediaWire
